ReviewOpen forum infectious diseases2024
Postacute Sequelae of COVID (PASC or Long COVID): An Evidenced-Based Approach.
Review in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Persistent inflammatory cytokine signature in long Covid-19 patients: a meta-analysis.Inflammopharmacology · 2026Pooled it
- Article
- Exercise and Cardiovascular Risk Modulation in Post-COVID Syndrome.Current atherosclerosis reports · 2026Review
- Spatial Immune Model of Alveolar Lung Infection (SIMALI) Identifies Structural Determinants of Lung Inflammation.Research square · 2026Article
- Can consumer wearables support outpatient health monitoring for patients with post-acute infection syndromes? A systematic umbrella review of accuracy, validity, and clinical utility data.PLOS digital health · 2026Article
- Article
- Outcomes of Patients with Neurocognitive Symptoms Attending a Long COVID Clinic: A Longitudinal Cohort Study.Journal of general internal medicine · 2026Article
- Complement System Dysregulation in the Immunopathogenesis of Long COVID: Systematic Evidence Synthesis.Biomedicines · 2026Review
- New-onset allergic diseases after SARS-CoV-2 infection: mechanistic hypotheses and emerging strategies for risk stratification.Frontiers in immunology · 2026Review
- Longitudinal trajectories of neurologic symptoms and cognitive associations at 36-months post-hospitalization for COVID-19.Frontiers in neurology · 2026Observational
- Long COVID in People With Multiple Sclerosis and Related Disorders: A Multicenter Cross-Sectional Study.Annals of clinical and translational neurology · 2025Article
- SARS-CoV-2-derived RNA replicons as safe and effective vaccines.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Review
- Serious Adverse Drug Reactions to COVID-19 Vaccines in the Pediatric Population: A Retrospective, Cross-Sectional Study Utilizing the Eudravigilance Database for the European Economic Area.Journal of clinical medicine · 2025Article
- Persistent Monocytic Bioenergetic Impairment and Mitochondrial DNA Damage in PASC Patients with Cardiovascular Complications.International journal of molecular sciences · 2025Article
- Preliminary evaluation of a mindfulness intervention program in women with long COVID dysautonomia symptoms.Brain, behavior, & immunity - health · 2025Article
- Post-acute sequelae of COVID-19 in residents in long-term care homes: Examining symptoms and recovery over time.PloS one · 2025Article
- Understanding the long-term interplay of SARS-CoV-2 immune and inflammatory responses with proteases in COVID-19 recovery: a longitudinal study.Frontiers in immunology · 2025Article
- IgA autoimmunity and coagulation among post-acute sequelae of SARS-CoV-2 infection (PASC) patients with persistent respiratory symptoms: a case-control study.Frontiers in immunology · 2025Article
- Risk factors for 1-year peripheral neuropathy and F-wave abnormalities after COVID-19: a prospective cohort study.Frontiers in neurology · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While the acute manifestations of infectious diseases are well known, in some individuals, symptoms can either persist or appear after the acute period. Postviral fatigue syndromes are recognized with other viral infections and are described after coronavirus disease 2019 (COVID-19). We have a growing number of individuals with symptoms that persist for weeks, months, and years. Here, we share the evidence regarding the abnormalities associated with postacute sequelae of COVID-19 (PASC) and therapeutics. We describe physiological and biochemical abnormalities seen in individuals reporting PASC. We describe the several evidence-based interventions to offer patients. It is expected that this growing understanding of the mechanisms driving PASC and the benefits seen with certain therapeutics may not only lead to better outcomes for those with PASC but may also have the potential for understanding and treating other postinfectious sequelae.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.